Dermatologists and plastic surgeons have a new, nonsurgical weapon to add to their anti-aging arsenal. Juvéderm Voluma XC was approved by the U.S. Food and Drug Administration in December as the first ...
The US Food and Drug Administration (FDA) has approved Juvéderm Voluma XC (Allergan) to correct age-related volume deficits in the midface in adults aged 21 years and older, the company announced ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Juvéderm Voluma XC as a filler to temporarily correct age-related loss in the cheeks of ...
IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE:AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLUMA™ XC, the ...
Please provide your email address to receive an email when new articles are posted on . “Because there are no permanent adverse reactions or deforming reactions, I think the safety is assured,” Karen ...
A US Food and Drug Administration (FDA) panel today unanimously recommended that the agency approve Juvéderm Voluma XC (Allergan) to correct age-related volume deficits in the mid-face. Juvéderm ...
Hyaluronic acid 20mg/mL, 0.3% w/w lidocaine; injectable gel implant. Should only be used by trained and experienced healthcare practitioners. Obtain patient's complete medical history prior to ...
At 3 months, findings showed 80.4% of patients treated with Juvéderm Voluma XC achieved at least a 1-point improvement in moderate to severe temple hollowing. The Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results